MicroRNA-9 restrains the sharp increase and boost apoptosis of human acute myeloid leukemia cells by adjusting the Hippo/YAP signaling pathway

References

• Bol P. [Acute myeloid leukemia]. Ned Tijdschr Tandheelkd. 2016;141:1748–1751.
   Google Scholar
• Cheng Y, Su Y, Wang S, et al. Identification of circRNA-lncRNA-miRNA-mRNA competitive endogenous RNA network as novel prognostic markers for acute myeloid leukemia. Genes. 2020;11:868.
   PubMed Web of Science ®Google Scholar
• Wang J, Chen S, Xiao W, et al. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J Hematol Oncol. 2018;11:7.
   PubMed Web of Science ®Google Scholar
• Song X, Peng Y, Wang X, et al. Incidence, survival, and risk factors for adults with acute myeloid leukemia not otherwise specified and acute myeloid leukemia with recurrent genetic abnormalities: analysis of the surveillance, epidemiology, and end results (SEER) database, 2001–2013. Acta Haematol. 2018;139:115–127.
   PubMed Web of Science ®Google Scholar
• Bauer M, Vaxevanis C, Heimer N, et al. Expression, regulation and function of microRNA as important players in the transition of MDS to secondary AML and their cross talk to RNA-binding proteins. Int J Mol Sci. 2020;21:7140.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu B, Zhang XP. Effects of miRNAs on functions of breast cancer stem cells and treatment of breast cancer. Onco Targets Ther. 2018;11:4263–4270.
   PubMed Web of Science ®Google Scholar
• Hummel R, Maurer J, Haier J. MicroRNAs in brain tumors. Mol Neurobiol. 2011;44:223–234.
   PubMed Web of Science ®Google Scholar
• Oorschot DV, Kuipers JE, Arentsen-Peters S, et al. Differentially expressed miRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2012;58:715–721.
   PubMed Web of Science ®Google Scholar
• Rashed RA, Hassan NM, Hussein MM. MicroRNA-92a as a marker of treatment response and survival in adult acute myeloid leukemia patients. Leuk Lymphoma. 2020;61:2475–2481.
   PubMed Web of Science ®Google Scholar
• Wang X, Feng Y, Zhang P, et al. miR-582-5p serves as an antioncogenic biomarker in intermediate risk AML with normal cytogenetics and could inhibit proliferation and induce apoptosis of leukemia cells. Cell Biol Int. 2020;44:2021–2030.
   PubMed Web of Science ®Google Scholar
• Nowek K, Sun SM, Dijkstra MK, et al. Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age. Leukemia. 2016;30:303–309.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Horiguchi H, Kikuchi S, et al. miR-7977 inhibits the Hippo-YAP signaling pathway in bone marrow mesenchymal stromal cells. PLoS One. 2019;14:e0213220.
   PubMed Web of Science ®Google Scholar
• Zhang H, Lang T, Zou D, et al. miR-520b promotes breast cancer stemness through Hippo/YAP signaling pathway. Onco Targets Ther. 2019;12:11691–11700.
   PubMed Web of Science ®Google Scholar
• Kang W, Huang T, Zhou Y, et al. miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis. Cell Death Dis. 2018;9:1–16.
   PubMed Web of Science ®Google Scholar
• Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: consensus document from ELN MRD working party. Blood. 2018;131:blood-2017-09-801498.
   Web of Science ®Google Scholar
• Rager JE, Fry RC. The aryl hydrocarbon receptor pathway: a key component of the microRNA-mediated AML signalisome. Int J Environ Res Public Health. 2012;9:1939–1953.
   PubMed Web of Science ®Google Scholar
• Gao SM, Xing CY, Chen CQ, et al. miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level. J Exp Clin Cancer Res. 2011;30:110.
   PubMed Web of Science ®Google Scholar
• Wang XS, Gong JN, Yu J, et al. MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. Blood. 2012;119:4992–5004.
   PubMed Web of Science ®Google Scholar
• Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015;15(6):321–333.
   PubMed Web of Science ®Google Scholar
• Khafaei M, Rezaie E, Mohammadi A, et al. miR‐9: from function to therapeutic potential in cancer. J Cell Physiol. 2019;234:14651–14665.
   PubMed Web of Science ®Google Scholar
• Chen L, Hu W, Li G, et al. Inhibition of miR-9-5p suppresses prostate cancer progress by targeting StarD13. Cell Mol Biol Lett. 2019;24:20.
   PubMed Web of Science ®Google Scholar
• Dong ZC, Zhang D, Wang SB, et al. Target inhibition on GSK-3β by miR-9 to modulate proliferation and apoptosis of bladder cancer cells. Eur Rev Med Pharmacol Sci. 2018;22:3018.
   PubMed Web of Science ®Google Scholar
• Chen W, Yu J, Xie R, et al. miR-9-5p increases sensitivity to cisplatin in thyroid cancer cells by down-regulating BRAF expression. J Biomater Tissue Eng. 2019;9:751–759.
   Web of Science ®Google Scholar
• Liu Y, Lei P, Qiao H, et al. miR-9 enhances the chemosensitivity of AML cells to daunorubicin by targeting the EIF5A2/MCL-1 axis. Int J Biol Sci. 2019;15:579–586.
   PubMed Web of Science ®Google Scholar
• Nishioka C, Ikezoe T, Pan B, et al. MicroRNA-9 plays a role in interleukin-10-mediated expression of E-cadherin in acute myelogenous leukemia cells. Cancer Sci. 2017;108:685–695.
   PubMed Web of Science ®Google Scholar
• Tian C, You MJ, Yu Y, et al. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1. Tumor Biol. 2016;37:7461–7471.
   PubMedGoogle Scholar
• Wang DY, Wu YN, Huang JQ, et al. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance. Chin J Cancer. 2016;35:47.
   PubMedGoogle Scholar
• Plouffe SW, Hong AW, Guan KL. Disease implications of the Hippo/YAP pathway. Trends Mol Med. 2015;21:212–222.
   PubMed Web of Science ®Google Scholar
• Lei Q, Zhang H, Zhao B, et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the Hippo pathway. Mol Cell Biol. 2008;28:2426–2436.
   PubMed Web of Science ®Google Scholar
• Zheng J, Peng B, Zhang Y, et al. miR-9 knockdown inhibits hypoxia-induced cardiomyocyte apoptosis by targeting Yap1. Life Sci. 2019;219:129–135.
   PubMed Web of Science ®Google Scholar
• Chen D, Sun Y, Wei Y, et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med. 2012;18:1511–1517.
   PubMed Web of Science ®Google Scholar